<SEC-DOCUMENT>0001193125-16-732974.txt : 20161007
<SEC-HEADER>0001193125-16-732974.hdr.sgml : 20161007
<ACCEPTANCE-DATETIME>20161006190602
ACCESSION NUMBER:		0001193125-16-732974
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20161006
FILED AS OF DATE:		20161007
DATE AS OF CHANGE:		20161006

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Prima BioMed Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		161925799

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		612 9276 1224

	MAIL ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d259003d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">6-K</FONT> </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF
FOREIGN PRIVATE ISSUER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13A-16</FONT> OR
<FONT STYLE="white-space:nowrap">15D-16</FONT> UNDER THE </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dated October&nbsp;6, 2016 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number <FONT STYLE="white-space:nowrap">001-35428</FONT> </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>P<SMALL>RIMA</SMALL> B<SMALL>IO</SMALL>M<SMALL>ED</SMALL> L<SMALL>TD</SMALL> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of Registrant&#146;s Name) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 12, 95 Pitt Street </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Sydney, 2000 New South Wales, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by
check mark whether the registrant files or will file annual reports under cover of Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT STYLE="white-space:nowrap">40-F.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
<FONT STYLE="white-space:nowrap">20-F&nbsp;&nbsp;</FONT><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form <FONT STYLE="white-space:nowrap">40-F&nbsp;&nbsp;</FONT><FONT
STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT
STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b) (1):&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by
Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b) (7):&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;
&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicate below the file number assigned to the
registrant in connection with Rule 12g3-2(b): Not applicable. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: October&nbsp;6, 2016 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B>Prima BioMed Ltd</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:25.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:75.45pt; font-size:8pt; font-family:Times New Roman"><B>Description of Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">PRIMA ABSTRACTS ACCEPTED FOR POSTER PRESENTATION AT ESMO SYMPOSIUM ON IMMUNO-ONCOLOGY</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d259003dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g259003g70o82.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media Release (Code: ASX: PRR; NASDAQ: PBMD) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6 October 2016 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PRIMA ABSTRACTS ACCEPTED FOR
POSTER PRESENTATION </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AT ESMO SYMPOSIUM ON IMMUNO-ONCOLOGY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SYDNEY, AUSTRALIA&#151;Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (&#147;Prima&#148;, the &#147;Company&#148;) announces that an abstract for each of its two
clinical trials for IMP321 has been accepted for Poster presentation (display) during the European Society for Medical Oncology (ESMO) Symposium on &#145;Immuno-Oncology&#151;Advances in cancer immunotherapy; From vaccines to antibodies and cell
therapies&#146; from 4-6&nbsp;November 2016 in Lausanne, Switzerland. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The abstract titles are: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">TACTI-mel (Two ACTive Immunotherapeutics in melanoma): A Phase 1 trial in patients with unresectable or metastatic melanoma receiving IMP321 (LAG-3Ig fusion protein) as an adjunctive therapy to anti-PD-1 therapy with
pembrolizumab (Poster #155); and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">AIPAC (Active Immunotherapy PAClitaxel): A Phase IIb trial in hormone receptor-positive metastatic breast carcinoma patients receiving IMP321 (LAG-3Ig fusion protein) or placebo as adjunctive to a standard chemotherapy
regimen of paclitaxel (Poster #145). </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Both posters will be on display for the duration of the Symposium. The Poster viewing session will
take place over lunch from 13:00-14:15 on Saturday 5&nbsp;November 2016. The abstracts will also be published in the ESMO Symposium on Immuno-Oncology 2016 Abstract Book, a supplement to the official ESMO journal &#147;Annals of Oncology&#148;.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more schedule information see <U>http://www.esmo.org/Conferences/Immuno-Oncology-2016</U> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Prima BioMed </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prima BioMed is a globally active
biotechnology company that is striving to become a leader in the development of immunotherapeutic products for the treatment of cancer. Prima BioMed is dedicated to leveraging its technology and expertise to bring innovative treatment options to
market for patients and to maximise value to shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prima&#146;s current lead product is IMP321, based on the LAG-3 immune control mechanism which
plays a vital role in the regulation of the T cell immune response. IMP321, which is a soluble LAG-3Ig fusion protein, is an APC activator boosting T cell responses. IMP321 is currently in a Phase II clinical trial as a chemoimmunotherapy for
metastatic breast cancer termed AIPAC (clinicaltrials.gov identifier <U>NCT 02614833</U>) and in a Phase I combination therapy trial in metastatic melanoma termed TACTI-mel (clinicaltrials.gov identifier <U>NCT 02676869</U>). A number of additional
LAG-3 products including antibodies for immune response modulation in autoimmunity and cancer are being developed by large pharmaceutical partners. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prima BioMed is listed on the Australian Securities Exchange, and on the NASDAQ in the US. For further
information please visit <U>www.primabiomed.com.au</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>For further information please contact: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Prima BioMed Ltd: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australia Investor/Media: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr Matthew Gregorowski, Citadel-MAGNUS </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 (2)&nbsp;8234 0100;
<U>mgregorowski@citadelmagnus.com</U> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Investors: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Matthew Beck, The Trout Group LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (646)&nbsp;378-2933;
mbeck@troutgroup.com </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Prima BioMed Ltd</B>,
Level 12, 95 Pitt Street, Sydney NSW 2000 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Phone: +61 2 8315 7003 Fax: +61 2 8569 1880 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">www.primabiomed.com.au ABN: 90 009 237 889 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g259003g70o82.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g259003g70o82.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 A('4XH 6@ H 3(!QF@
M!: "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * ,_6=8L]"TR:_OI1'#$,DGO["F!R_A*^U3Q<[:Y?![
M6P5R+2W'&\?WVH W-;\4Z;H*A;J7,IZ1KR:RJ58PW.W"X*KB7[BT.<3XIZ<T
MNUK254_O5SK%1['J/(JJC=2U.A6ZLO%6D$V5RRGJK(V&1NU=,9J2NCQ:^'J8
M>7+45C!\,^.6?6YO#6O;8-6@;"-T68=B/>M# [R@ I &:8!2 * $S0 4 +0
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MI@=)\-_B1KE[XG;PYXB0/<$E0^,%6'8T /UOQEKMI\9(-#AO"NGLZ Q;?44
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M]A%OJ*+G /#XZXH ])I % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 ?*_P 4([C2OBC=73J5S(LJ'U%,#Z2\-ZQ;
M:[H%I?VTJR))&,[>QQR* *WB#PEI_B!09U\N8=)%ZUE4I1GN=V$QU7"OW=CF
M4^%-L'^>_<IZ!:YEA$GN>J\^J-643LM'T2ST.S6WM$ '=N[?6NN$%!61XF(Q
M%3$3YIL\,^/'B.VOM5M-'MWWM:9:4CH">U6<YZ?\)K:2V^'FFB3(+ L ?3-
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M\<^*I'^$VC6,?F&[OXE#;0<A1US0!/X5^"MC=^'+.ZO[RZANYT#ND;X STH
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MW>D 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@!.*8'S1\7?$JZIXIFTK
M38DCCC8)*Z##3/Z'Z4 <3K7A?6/#0MGU.U\D3C?&3R"* /I_X:ZU9ZWX+LIK
M2!(/+7RY(T& &'6@#KZ0!0 4P"@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "D 4 % !0 4 % 'FD?Q,N0/WEBA^C5P?
M6GV/HWD\>DBW#\3(B1YMBP^C52Q:['/+)Y])&C#\0])D WK*A]Q5K$Q,I956
M6Q=C\;:)(/\ CZV_5:M5X=S!Y=B%T+,?BG19#@7\0/N<5:K0?4REA*\=XEV+
M5;"89CNX3_P,57/'N9.C46\63+<PM]V9#]&%4FF0X270D5@>A!H)LT.H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@!K#*$ X)%,#P#P=X/67XQ:E#JT>\
MVK-.BMT;)X- 'J/Q)T.TU?P1J GC3?;Q&2-R.5(]* ,#X&V-Q9^"7DG1D6>8
MO'D8R/6@#T^D 4 %, H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M0 4P"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M 4 +0 4 %, I % !0 4P"D 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M%, I )0 4 +3 * "D E "T )3 "P'4BD!&]Q#&,O*BCW-*Z*49/9%636=.B^
M_>PK]7%+GBNI:HU);(K2>*=$B'S:C"/^!5/M8+J;+!UW]EE.;QWX?A!_TT/C
M^ZI-0\1!&T,LQ,]HF5/\4-)CR(8)Y?PQ4/%01T1R;$/>Q0D^*T?_ "RTYO\
M@35'UM=$="R27610N/BEJ#@B&SB3W)S4/%2Z(Z(9-27Q,Q[CQ]K\QXN1&/\
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MF>B_\_!_[YH^L4^X?V?B/Y1?^$RT7_GY/_?-'UBGW%_9^(_E#_A,]$_Y^O\
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M0QB'I2 ::!C>E #30,;TH&)0,:: $H*0TT A*!C30 E Q*!C#0 AH&)0 AH
M0T#0WO0,#0 V@84 )S0 E "4 % Q#0,* "@ H&-/6@!#0 4 % !0 4 -H *
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M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 )0 4P#%
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M: &T#$/6@8E 6$H&'- "4 (: $H *"A* "@04 (:"A*  T )0 4 % !0 V@
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M5AU4BE8JZ"@+C:!A0 4 ?2]>X?G 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
1 4 % !0 4 % !0 4 % '_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
